Expression of MGMT mRNA was significantly reduced, by 83% in BTZ+TMZ 164 mg/m2 compared with TMZ 164 mg/m2 monotherapy treated tumours, 65% compared with BTZ+TMZ 82 mg/m2 and 37% compared with TMZ 82 mg/m2 (P < 0.01 for all, Fig. 4f), indicating successful target inhibition in vivo. This evidence concerns the gene MGMT and neoplasm.